NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

OCS

Oculis Holding AG

Apr 25 • 04:00PM ET

17.00

Dollar change -1.05
Percentage change -5.82	%

Healthcare • Biotechnology • Switzerland • NASD

Peers: SNY VRTX PFE BMY REGN BMRN NBIX GEN RGEN EBS

| Held by: SMLV GLCR

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.39	Insider Own	31.53%	Shs Outstand	43.66M	Perf Week	-6.95%
Market Cap	816.00M	Forward P/E	-	EPS next Y	-2.16	Insider Trans	0.00%	Shs Float	32.87M	Perf Month	-13.53%
Income	-97.41M	PEG	-	EPS next Q	-0.52	Inst Own	2.94%	Short Float	0.15%	Perf Quarter	-24.48%
Sales	0.00M	P/S	-	EPS this Y	14.60%	Inst Trans	-22.60%	Short Ratio	1.01	Perf Half Y	7.53%
Book/sh	1.85	P/B	9.17	EPS next Y	1.29%	ROA	-72.51%	Short Interest	0.05M	Perf Year	42.26%
Cash/sh	2.27	P/C	7.50	EPS next 5Y	27.93%	ROE	-101.29%	52W Range	10.79 - 23.08	Perf YTD	0.00%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-118.89%	52W High	-26.34%	Beta	0.10
Dividend TTM	-	Quick Ratio	2.37	Sales past 5Y	0.00%	Gross Margin	-	52W Low	57.55%	ATR (14)	0.82
Dividend Ex-Date	-	Current Ratio	2.37	EPS Y/Y TTM	-2737.27%	Oper. Margin	-	RSI (14)	42.47	Volatility	3.60% 5.19%
Employees	49	Debt/Eq	0.02	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.12	Target Price	33.30
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-98.65%	Payout	-	Rel Volume	1.27	Prev Close	18.05
Sales Surprise	-98.52%	EPS Surprise	-44.84%	Sales Q/Q	-	Earnings	Mar 11 AMC	Avg Volume	50.16K	Price	17.00
SMA20	-1.96%	SMA50	-9.36%	SMA200	5.29%	Trades		Volume	63,796	Change	-5.82%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-05-23	Initiated	Chardan Capital Markets	Buy	$30
Oct-05-23	Initiated	Stifel	Buy	$35
Jun-14-23	Initiated	BofA Securities	Buy	$22
Jun-12-23	Initiated	H.C. Wainwright	Buy	$28
Jun-08-23	Initiated	Robert W. Baird	Outperform	$58
May-10-23	Initiated	Pareto	Buy	$23
Apr-28-23	Initiated	Wedbush	Outperform	$27

Apr-25-25 04:00PM	Oculis Updates Share Capital (GlobeNewswire) -5.82%
Apr-17-25 05:00AM	Oculis and EURETINA Announce the 2025 Ramin Tadayoni Award (GlobeNewswire)
Apr-15-25 04:00AM	Oculis Hosts R&D Event Today to Showcase Progress on All Three Pipeline Assets (GlobeNewswire)
Apr-10-25 08:00AM	Oculis Completes Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema (GlobeNewswire)
Apr-09-25 05:00PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire) +9.73%
12:25PM	Loading…
Apr-03-25 12:25PM	A First Look At Oculis Holding AG: Revenues Still Several Years Away (Seeking Alpha)
Apr-01-25 04:00AM	Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond (GlobeNewswire)
Mar-30-25 07:10AM	abrdn World Healthcare Fund Q4 2024 Commentary (Seeking Alpha)
03:25AM	abrdn Healthcare Opportunities Fund Q4 2024 Commentary (Seeking Alpha)
Mar-20-25 06:01PM	Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities (GlobeNewswire)
Mar-14-25 04:31PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Mar-11-25 04:30PM	Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update (GlobeNewswire)
Mar-05-25 04:00AM	Oculis to Present at Upcoming March Investor Conference (GlobeNewswire) +5.50%
Mar-03-25 03:18AM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
Feb-13-25 07:40PM	Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares (GlobeNewswire)
06:35PM	Loading…
Feb-07-25 06:35PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated (GlobeNewswire)
Jan-31-25 04:00PM	Oculis updates share capital for its existing at-the-market offering program (GlobeNewswire)
Jan-21-25 04:00PM	Oculis Publishes Notification of Major Changes in Voting Rights (GlobeNewswire)
Jan-20-25 05:00PM	Oculis Publishes Notification of Major Changes in Voting Rights (GlobeNewswire)
Jan-06-25 05:30PM	Oculis Trial Shows Potential for Optical Neuroprotective Therapy (Exec Edge)
03:53AM	Oculis Announces Positive OCS-05 Phase 2 ACUITY Trial in Acute Optic Neuritis, Met Primary Safety Endpoint and Key Secondary Efficacy Endpoints Opening Development Pathways as a Potential First-in-Class Neuroprotective Therapy (GlobeNewswire)
Jan-03-25 06:48PM	Oculis Publishes Notification of Major Changes in Voting Rights (GlobeNewswire)
Dec-06-24 04:00PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire) +5.66%
Nov-29-24 04:00AM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated (GlobeNewswire)
Nov-27-24 04:15AM	Oculis Publishes Notification of Transaction by Person Discharging Managerial Responsibilities (GlobeNewswire) +5.14%
Nov-13-24 04:00AM	Oculis to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-07-24 04:00AM	Oculis Reports Q3 2024 Financial Results and Provides Company Updates (GlobeNewswire)
Oct-21-24 01:04PM	Oculis Accelerates Enrollment in both DIAMOND Phase 3 Trials of OCS-01 in Diabetic Macular Edema and Expands its DIAMOND Program Committees (GlobeNewswire) +18.10%
Oct-15-24 04:00AM	Oculis' DIAMOND Phase 3 Program in Diabetic Macular Edema to be Presented at Innovate Retina and Eyecelerator 2024 (GlobeNewswire)
Oct-02-24 04:00AM	Oculis Announces Appointment of Daniel S. Char as Chief Legal Officer (GlobeNewswire)
01:00PM	Loading…
Sep-19-24 01:00PM	Oculis and EURETINA Announce the Winner of the Inaugural Ramin Tadayoni Award (GlobeNewswire)
Aug-29-24 04:00AM	Oculis to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-27-24 04:00PM	Oculis Publishes Consolidated Q2 Financial Statements and MD&A (GlobeNewswire)
04:00AM	Oculis Reports Q2 2024 Financial Results and Provides Recent Company Update (GlobeNewswire)
Aug-15-24 08:00AM	Oculis Appoints Sharon Klier, M.D., M.S., M.P.H. as Chief Development Officer (GlobeNewswire)
Jul-30-24 04:10PM	Oculis to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) -5.69% +6.03%
Jun-27-24 06:30AM	Oculis and EURETINA Announces the Ramin Tadayoni Award (GlobeNewswire)
Jun-10-24 05:00AM	Oculis Announces Positive Topline Results of Phase 2b RELIEF Trial with Licaminlimab, Designed to Transform the Treatment Paradigm of Dry Eye Disease with a Precision Medicine Strategy (GlobeNewswire)
Jun-04-24 01:47PM	Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities (GlobeNewswire)
May-30-24 04:00AM	Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board (GlobeNewswire)
May-18-24 09:07AM	OCS Stock Earnings: Oculis Holding Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-17-24 04:30PM	Oculis updates share capital for its existing at-the-market offering program (GlobeNewswire)
May-08-24 04:10PM	Oculis Reports Q1 2024 Financial Results and Provides Company Updates (GlobeNewswire)
04:05PM	Oculis Announces Completion of Enrollment in Phase 2 Randomized Controlled ACUITY Trial with OCS-05 for Acute Optic Neuritis (GlobeNewswire)
May-07-24 04:05PM	Oculis Publishes Invitation to the Annual General Meeting (GlobeNewswire)
May-06-24 06:30AM	Oculis to Present at Bank of America Global Healthcare Conference (GlobeNewswire)
Apr-29-24 04:05PM	Oculis Publishes Invitation to the Annual General Meeting (GlobeNewswire) +5.91%
Apr-22-24 09:27AM	Oculis Announces Closing of Registered Direct Offering and Commencement of Trading on Nasdaq Iceland Main Market (GlobeNewswire)
Apr-11-24 08:55AM	Oculis Announces Completion of Oversubscribed $59 Million Registered Direct Offering and Subsequent Listing on Nasdaq Iceland Main Market (GlobeNewswire)
Apr-10-24 06:30AM	Oculis Strengthens its Executive Leadership Team with the Appointment of Snehal Shah, Pharm.D. as President of Research & Development (GlobeNewswire) +6.18%
Apr-08-24 06:30AM	Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting (GlobeNewswire)
Apr-04-24 06:30AM	Oculis to Participate at Upcoming April Investor Conferences (GlobeNewswire)
Mar-18-24 06:30AM	Oculis Reports Q4 and Full Year 2023 Financial Results and Update on Company Progress (GlobeNewswire)
Feb-28-24 06:30AM	Oculis Provides Updates at R&D Day on Late-Stage Clinical Trials and Announces Key Leadership Appointments (GlobeNewswire)
Feb-01-24 09:55AM	How Much Upside is Left in Oculis Holding AG (OCS)? Wall Street Analysts Think 152.77% (Zacks)
Jan-29-24 08:50AM	What Makes Oculis Holding AG (OCS) a Good Fit for 'Trend Investing' (Zacks)
06:30AM	Oculis to Present at Upcoming February Investor Conferences (GlobeNewswire)
Jan-22-24 06:30AM	Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024 (GlobeNewswire)
Jan-16-24 09:55AM	Can Oculis Holding AG (OCS) Climb 191.31% to Reach the Level Wall Street Analysts Expect? (Zacks)
Dec-20-23 06:30AM	Oculis Announces First Patient First Visit in Phase 3 OPTIMIZE-2 Trial of OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery (GlobeNewswire)
Dec-18-23 06:30AM	Oculis Announces First Patient First Visit in Phase 3 DIAMOND-1 Trial of OCS-01 Eye Drop in Diabetic Macular Edema (GlobeNewswire)
Dec-07-23 06:30AM	Oculis Announces First Patient First Visit in Phase 2b RELIEF Trial of Topical Anti-TNF Licaminlimab (OCS-02) in Dry Eye Disease (GlobeNewswire)
Nov-15-23 06:30AM	Oculis Reports Q3 2023 Financial Results and Provides Company Update (GlobeNewswire)
Nov-08-23 06:30AM	Oculis to Present at Upcoming November Investor Conferences (GlobeNewswire)
Nov-01-23 06:30AM	Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema (GlobeNewswire) -7.14%
Oct-10-23 06:30AM	Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress (GlobeNewswire)
Oct-05-23 06:30AM	Oculis to Present a Late-Breaking Abstract at the 23rd EURETINA Congress on Positive Phase 3 Stage 1 DIAMOND Trial Results for Diabetic Macular Edema (GlobeNewswire)
Sep-11-23 06:30AM	Oculis Expands its Executive Leadership Team and Appoints Rebecca Weil, Ph.D. as Chief Commercial Officer as it Enters Pre-Commercial Phase (GlobeNewswire)
Aug-30-23 06:30AM	Oculis to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-29-23 06:30AM	Oculis Reports Q2 and First Half 2023 Financial Results and Provides Company Update (GlobeNewswire)
Aug-08-23 06:30AM	OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Both Primary Endpoints in Phase 3 OPTIMIZE Trial with a Once Daily Regimen for the Treatment of Inflammation and Pain Following Cataract Surgery (GlobeNewswire)
Aug-02-23 08:00AM	First Patient Enrolled in LEOPARD, an Investigator-Initiated Trial, with OCS-01 Eye Drops for the Treatment of Cystoid Macular Edema (GlobeNewswire)
Jul-26-23 08:00AM	Oculis Announces to Present at Upcoming August Investor Conferences (GlobeNewswire)
Jul-19-23 08:00AM	Oculis to Present at OIS Retina Innovation Summit (GlobeNewswire)
Jun-26-23 08:00AM	Oculis to Host an R&D Retina Day to Showcase Clinical Programs Targeting Diabetic Macular Edema and Other Retina Diseases on Tuesday, July 11, 2023 (GlobeNewswire)
Jun-13-23 04:01PM	Oculis Announces Partial Exercise of Underwriters Option to Purchase Additional Ordinary Shares (GlobeNewswire)
Jun-12-23 08:00AM	Oculis Wins the 2023 Icelandic Knowledge Award from the Icelandic Association of Business and Economics (GlobeNewswire)
Jun-01-23 12:45PM	Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease (Newsfile)
08:00AM	Oculis to Participate in Jefferies Healthcare Conference (GlobeNewswire)
May-31-23 11:59PM	Oculis Announces Pricing of $40.25 Million Public Offering of Ordinary Shares (GlobeNewswire)
May-30-23 07:06AM	Oculis Announces Launch of Proposed Public Offering of Ordinary Shares (GlobeNewswire) -7.75%
May-24-23 08:00AM	Oculis to Participate and Present at Upcoming EuDES Meeting (GlobeNewswire)
May-22-23 06:30AM	Oculis Announces Positive Top Line Results from DIAMOND Stage 1 Phase 3 Trial in Diabetic Macular Edema with OCS-01 Eye Drops (GlobeNewswire) +5.29%
May-11-23 08:00AM	Oculis Co-founders Selected as Finalists in European Inventor Award 2023 (GlobeNewswire)
Apr-26-23 07:00AM	Oculis Opens New Offices in the US and Expands its US Team by Appointing Dr. Fang Li as Senior Vice President, Regulatory Affairs (GlobeNewswire)
Apr-05-23 07:00AM	Oculis to Participate at Upcoming Investor Conferences (GlobeNewswire)
Apr-04-23 07:00AM	Oculis to Host Conference Call on April 13, 2023 to Discuss Late-Stage Pipeline and Near-Term Clinical Milestones (GlobeNewswire)
Mar-22-23 07:00AM	Oculis to Ring Nasdaq Stock Market Opening Bell in Celebration of its Successful Listing (GlobeNewswire) -7.01%
Mar-16-23 09:45AM	Oculis Completes Enrollment in Phase 3 OCS-01 OPTIMIZE Trial (GlobeNewswire)

Oculis Holding AG is a global biopharmaceutical company, which engages in sight and improving eye care. The firm's pipeline includes multiple product candidates in development such as, OCS-01, a topical retinal candidate for diabetic macular edema, OCS-02, a topical biologic candidate for dry eye disease, and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company was founded in 2016 and is headquartered in Zug, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Sherif Riad	Officer	Mar 14 '25	Proposed Sale	18.66	25,000	466,500		Mar 14 04:10 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

OCS

Oculis Holding AG

Upgrade your FINVIZ experience